1stOncology™: Cancer Intelligence Service – Page 14378 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 2, 2019

On April 25, 2019 Novavax, Inc. (Nasdaq: NVAX) reported it will report its first quarter 2019 financial and operating results following the close of U.S. financial markets on Thursday, May 2, 2019 (Press release, Novavax, APR 25, 2019, http://ir.novavax.com/news-releases/news-release-details/novavax-host-conference-call-discuss-first-quarter-financial-2 [SID1234535419]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Conference call details are as follows:

Date: May 2, 2019
Time: 4:30 p.m. U.S. Eastern Time (ET)
Dial-in number: (877) 212-6076 (Domestic) or (707) 287-9331 (International)
Passcode: 5394082
Webcast: www.novavax.com, "Investors"/ "Events"

Conference call and webcast replay:

Dates: Starting at 7:30 p.m. ET, May 2, 2019 until 7:30 p.m. ET May 9, 2019
Dial-in number: (855) 859-2056 (Domestic) or (404) 537-3406 (International)
Passcode: 5394082
Webcast: www.novavax.com, "Investors"/ "Events", until August 2, 2019

Cytokinetics to Announce First Quarter Results on May 9, 2019

On April 25, 2019 Cytokinetics, Incorporated (Nasdaq:CYTK) reported that it is scheduled to report first quarter results on May 9, 2019 at 4:00 PM Eastern Time (Press release, Cytokinetics, APR 25, 2019, View Source [SID1234535418]). Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future.

The conference call will be simultaneously webcast and can be accessed from the homepage and in the Investors & Media section of Cytokinetics’ website at www.cytokinetics.com. The live audio of the conference call can also be accessed by telephone by dialing either (866) 999-CYTK (2985) (United States and Canada) or (706) 679-3078 (international) and typing in the passcode 4486595.

An archived replay of the webcast will be available via Cytokinetics’ website until May 16, 2019. The replay will also be available via telephone by dialing (855) 859-2056 (United States and Canada) or (404) 537-3406 (international) and typing in the passcode 4486595 from May 9, 2019 at 7:30 PM Eastern Time until May 16, 2019.

IntelGenx to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference

On April 25, 2019 IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"), a leading oral drug delivery company, reported that its Executive Vice-President and Chief Financial Officer, Andre Godin, is scheduled to present at the 2019 Bloom Burton & Co. Healthcare Investor Conference on April 30, 2019 at 2:30 p.m. ET at the Metro Toronto Convention Centre (Press release, IntelGenx, APR 25, 2019, View Source;Co-Healthcare-Investor-Conference/default.aspx [SID1234535416]).

Mr. Godin will provide an overview of IntelGenx’s business during the presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

The presentation will be webcast live and archived for 90 days on the Company’s website, at www.intelgenx.com, under "Presentations".

GlycoMimetics to Report First Quarter 2019 Financial Results on May 2, 2019

On April 25, 2019 GlycoMimetics, Inc. (NASDAQ: GLYC) reported that it will host a conference call and webcast to report its first-quarter 2019 financial results on Thursday, May 2, 2019, at 8:30 a.m. ET (Press release, GlycoMimetics, APR 25, 2019, View Source [SID1234535415]).

The dial-in number for the conference call is (844) 413-7154 (U.S. and Canada) or (216) 562-0466 (international) and entering passcode 1096657. To access the live audio webcast, or the subsequent archived recording, visit the "Investors – Events & Presentations" section of the GlycoMimetics website at www.glycomimetics.com. The webcast will be recorded and available for replay on the GlycoMimetics website for 30 days following the call.

Andarix Pharmaceuticals to Present at Neosynth Breast Cancer Conference

On April 25, 2019 Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer reported that it will present at the Neosynth Breast Cancer Conference in Boston MA on April 24-25th 2019 (Press release, Andarix Pharmaceuticals, APR 25, 2019, View Source [SID1234535414]).
The presentation will address the ability of theranostic technology to provide personalized medicine to diagnose and treat breast cancer. The three main types of breast cancer are defined by specific biomarkers and are over-expressed in the disease. The Andarix drug Tozaride targets somatostatin receptors on breast cancer cells and represents a new target for breast cancer therapy. The company will present clinical data to support the biomarker application.

About Tozaride
Tozaride is a novel, best-in-class cancer therapy based on a radio-labeled somatostatin peptide analogue. Early clinical studies of Tozaride demonstrated that it is well tolerated and may produce prolonged stable disease and improved overall survival in advanced lung cancer patients whose disease has continued to progress after failing other therapies. Tozaride targeted radiotherapy represents a new treatment paradigm which is expected to yield significant clinical benefit for both lung cancer (SCLC, NSCLC), and pancreatic cancer patients. Along with its companion diagnostic that helps identify patients most likely to respond – those with enough expression of the peptide’s target – Tozaride could provide another treatment option for patients who are not eligible for, or who have not responded to current therapies.